Tag
A comprehensive meta-analysis of the POTOMAC, CREST, and ALBAN trials reveals that adding PD-(L)1 inhibitors to BCG improves event-free survival in high-risk NMIBC. However, increased toxicity and agent-specific variations in efficacy sugge
A global cluster randomized trial (RESECT) demonstrates that while audit and feedback improve surgical documentation in non-muscle-invasive bladder cancer, they fail to enhance detrusor muscle sampling, adjuvant chemotherapy use, or early r
The phase III ALBAN trial found no benefit in adding atezolizumab to BCG for BCG-naive high-risk NMIBC, emphasizing that immunotherapy benefits in this space are likely agent-specific and necessitate better biomarker-driven selection.
A phase II trial assessing oral metformin for low-grade non-muscle-invasive bladder cancer (NMIBC) found minimal antitumor activity and no significant mechanistic changes, challenging metformin’s role as an intravesical therapeutic agent in
